Sanofi, Formation Bio and OpenAI enter AI collaboration

Betsy Goodfellow | May 22, 2024 | News story | Research and Development Formation Bio, OpenAI, Pharmacy, Sanofi, collaboration 

Sanofi, Formation Bio and OpenAI have announced that they have entered into a collaboration with the aim of building AI-powered software to accelerate the drug development process and bring new drugs to market and to patients more efficiently.

The three parties plan to ‘bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle’, according to the press release.

This first-of-a-kind collaboration will enable Sanofi to provide access to proprietary data for the development of AI models, marking part of the company’s plan to become the first biopharma company powered by AI at scale.

OpenAI are expected to contribute access to its cutting-edge AI capabilities, while Formation Bio will contribute its extensive engineering resources, as well as its experience at the intersection of the pharma and AI industries.

Paul Hudson, chief executive officer at Sanofi, commented: “This unique collaboration is the next significant step in our journey to becoming a pharmaceutical company substantially powered by AI. Next generation, first-of-its kind AI model customisations will be an important foundation in our efforts to shape the future of drug development for pharma and for the many patients waiting for innovative treatments.”

Brad Lightcap, chief operating officer at OpenAI, added: “There is massive potential for AI to accelerate drug development. We are excited to collaborate with Sanofi and Formation Bio to help patients and their families by bringing new medicines to market.”

Betsy Goodfellow

Related Content

testalize-me-0je8ynv4mis-unsplash

Sanofi shares phase 3 trial results for Sarclisa in multiple myeloma treatment

Sanofi has announced data from the IMROZ phase 3 trial which assessed Sarclisa (isatuximab) in …

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery …

Fulcrum Therapeutics and Sanofi enter collaboration for facioscapulohumeral muscular dystrophy treatment

Fulcrum Therapeutics has announced that it has entered into a collaboration and license agreement with …

Latest content